Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators. Bakris GL, et al. Among authors: shi v. Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. Epub 2010 Feb 18. Lancet. 2010. PMID: 20170948 Clinical Trial.
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K. Weber MA, et al. Among authors: shi v. Blood Press. 2007;16(1):13-9. doi: 10.1080/08037050701217643. Blood Press. 2007. PMID: 17453747 Free article. Clinical Trial.
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Bakris G, Hester A, Weber M, Dahlof B, Pitt B, Velasquez E, Staikos-Byrne L, Shi V, Jamerson K; ACCOMPLISH Investigators. Bakris G, et al. Among authors: shi v. J Cardiometab Syndr. 2008 Fall;3(4):229-33. doi: 10.1111/j.1559-4572.2008.00023.x. J Cardiometab Syndr. 2008. PMID: 19040592 Free article. Clinical Trial.
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M; ACCOMPLISH Investigators. Jamerson K, et al. Among authors: shi v. Blood Press. 2007;16(2):80-6. doi: 10.1080/08037050701395571. Blood Press. 2007. PMID: 17612905 Free article. Clinical Trial.
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M; Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension Investigators. Kjeldsen SE, et al. Among authors: shi v. Blood Press. 2008;17(1):7-17. doi: 10.1080/08037050801972857. Blood Press. 2008. PMID: 18568687 Free article. Clinical Trial.
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. Solomon SD, et al. Among authors: shi v. Lancet. 2012 Oct 20;380(9851):1387-95. doi: 10.1016/S0140-6736(12)61227-6. Epub 2012 Aug 26. Lancet. 2012. PMID: 22932717 Clinical Trial.
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Seferovic JP, et al. Among authors: shi vc. Lancet Diabetes Endocrinol. 2017 May;5(5):333-340. doi: 10.1016/S2213-8587(17)30087-6. Epub 2017 Mar 18. Lancet Diabetes Endocrinol. 2017. PMID: 28330649 Free PMC article. Clinical Trial.
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. McMurray JJ, et al. Among authors: shi vc. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. N Engl J Med. 2014. PMID: 25176015 Free article. Clinical Trial.
460 results